The company gave investors a closer look at its eczema candidate and they liked what they saw.
Investors digesting a late-breaking data drop pushed up the stock.
Some investors think the market's been too hard on these drugmakers.
These aren't the highest payouts in the industry, but they have the best chance to steadily climb.
A bullish Wall Street analyst thinks it can.
Could these biopharmaceutical giants continue growing if they stopped hiking up drug prices?
Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.
These aren't the most exciting businesses in the sector, but you're going to love their steadily growing dividends.
These three healthcare pioneers have slid down to nice prices that investors should take advantage of this month.
A survey of allergists suggests Palforzia's launch could be more successful than expected.
These small-cap biotechs have fallen to bargain prices.
The company released some positive data yesterday...that wasn't positive enough.
These are the companies best positioned to survive a bear attack.
Stockholm-based Sobi wants to expand its U.S. presence, beginning with Dova's platelet therapy.
Here's why a fearless marijuana stock analyst thinks investors are still too optimistic about the next two years.
America's largest pharmaceutical company is going through some big changes.
Amazon's new pilot program looks like a shot across the bow of Teledoc and its peers.
August sales figures suggest the company's strategy is working.
Is it time to take advantage of a recent pullback, or is this a falling knife you don't want to catch?
Investors are thrilled with a new addition to BioCryst's board of directors.